Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL (BeGeRN)
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab Combination (BeGeRN) in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor: St. Petersburg State Pavlov Medical University
Listed as NCT03259529, this PHASE1/PHASE2 trial focuses on Diffuse Large B Cell Lymphoma and remains completed. Sponsored by St. Petersburg State Pavlov Medical University, it has been updated 9 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
May 2019 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- St. Petersburg State Pavlov Medical University
For direct contact, visit the study record on ClinicalTrials.gov .